Company brings successful lab approach from Europe to provide comprehensive solutions to North American customers at Bloomington site
ATMI, a leader in single-use bioprocess solutions, has opened a US-based laboratory for applications development and testing as part of the company’s strategy of implementing interactive, long-term customer support along with its innovative single-use disposable technologies.
Located inside its Bloomington, MN manufacturing facility, the lab will support process operations using the full ATMI LifeSciences portfolio of single-use bioprocess solutions, including bioprocess vessels, bioreactors, mixers and its fill/finish platform.
The site is a duplicate of ATMI’s original laboratory located in Brussels, Belgium. The Belgian lab was introduced in 2008 to develop and validate the Integrity iCELLis and Xpansion bioreactors. However, the scope of the lab quickly grew to include full support services for all ATMI LifeSciences technologies.
With the addition of the new 100m2, fully equipped Bloomington laboratory, ATMI has extended this depth of support to US-based customers. Together, the labs offer direct access to the expertise of 15 global application specialists and scientists that are dedicated to working on customer bioprocess development efforts.
The new Bloomington lab features development and operations support in a round-the-clock format. Customers taking advantage of the lab can benefit from the ability to align directly with application staff to develop and optimise processes, test bioprocess applications, scale-up individual cell culture processes for technical transfer, learn through demonstrations how ATMI technologies work, and receive any further training that may be needed.
‘The new location is a clear reflection of ATMI’s strategy to provide comprehensive bioprocess solutions and invest in customer support,’ said Senior Vice President and General Manager of ATMI LifeSciences, Mario Phillips. ‘The laboratory is fully equipped with ATMI technologies and equipment to perform cell culture, and it is staffed by experts in the field.
‘The team at this site has extensive experience in cell culture bioprocesses development and scale-up, as well as more than 20 protein, virus and cell production processes that have been developed in ATMI’s proprietary bioreactors. The team will be fully focused on understanding the challenges that customers are faced with and applying their technical knowledge to offer guidance.’